Viral-based immunotherapies to transform the fight against cancers and infectious diseases

November 2017Corporate Presentation

This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties,which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) theresults of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currentlyunder way, (ii) regulatory authorities will agree with the Company’s further development plans for its therapies, or(iii) the Company will find development and commercialization partners for its therapies in a timely manner and onsatisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negativeoutcome for the Company’s activities, perspectives, financial situation, results and development.

For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition,performance or achievements to differ from those contained in the forward-looking statements, please refer to theRisk Factors (“Facteurs de Risque") section of the Document de Référence, available on the AMF website(http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speakonly as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Disclaimer

2

Management | Experienced team focused on delivery

3

Philippe Archinard, PhDChairman & Chief Executive Officer

Eric Quéméneur, PhDExecutive VP and Chief Scientific Officer

Christophe Ancel, PharmDVP Quality and Qualified Person

Maud Brandely, MD, PhDChief Medical Officer

Jean-Philippe DelVP Finance

Thibaut du Fayet, MBAVP Marketing, Alliance, and Project Mgt

John Felitti, JD, MBAGeneral Counsel and VP Legal

Hemanshu Shah, PhD, MBAVP Corporate Development & Medical Affairs

E

C

D

A

B

F

EC DA B F

Transgene | Poised to play a key role in immunotherapy

4

A pioneer in developing viral vector-based immunotherapies

2Cutting-edge immunotherapy platforms

• Therapeutic vaccines• Oncolytic viruses

Focus on cancers and infectious diseases:

• High level of unmet medical need

• New treatments leave significant opportunities

5Immunotherapy products

in clinical trials – focus on combinations

Anti-PD-1/PD-L1 | A new paradigm – need for improvementTargeting substantial non-responder populations

5

0

50

100

OR

R %

ORR = approximate objective response rate %

FDA approved agent available

Transgene’s indications of interest

Source: from ASCO Annual meeting 2017, by Gregory L. Beatty, MD PhD

*Anti-PD-1 FDA approved in Sept. 2017

Non-responders

The power of immunotherapy combinationsStrong scientific rationale for adding our immunotherapies to ICIs

6

Immune Checkpoints Inhibitors (ICIs)

Positive effects of the combination of Transgene’s immunotherapies with ICIs have been demonstrated in several preclinical tumor models

Increased response rate, longer duration of response, extended OS

Block the signal that preventsactivated T-cells from attacking cancer cells

Enhance the efficacy of anti-tumor T-cell response Need for increased response rate

Therapeutic Vaccines Stimulate the immune response to kill cancer cells

Oncolytic Viruses Directly attack tumor cells and boost the immune system

Safety - Preserve healthy cells

Transgene’s immunotherapies

Compelling preclinical and clinical packages

Readouts expectedon 5 products

Sep 2017Launch OV platformfor a new generation OV

Transgene | Building momentum in immuno-oncologyClinical collaborations validate the potential of ICI+TG immunotherapy combinations

7

2016 2017 2018

Clinical collaborations made possible by Transgene’s compelling clinical and pre-clinical packages

Oct 2016Clinical collaboration

for TG4001

Dec 2016Clinical collaboration

for TG4010 (NSCLC 2L)

Apr 2017Clinical collaborationfor TG4010 (NSCLC 1L)

Refocused clinical development on combination trials with ICIs

Jun 2017Research

collaboration agreement for

UCART-19 production

7 clinical trials initiated in last 18 months

Diversified portfolio of clinical-stage immunotherapies

8

Product IndicationPreclinical Clinical Phase

Major Expected Milestones1 2 3

THERAPEUTIC VACCINES

TG4010

Non-small cell lung cancer – 1st line

Non-small cell lung cancer – 2nd line

Non-small cell lung cancer

FPI YE17

First data 1Q 2018

TG4001 HPV positive cancers First data in 2H 18

TG1050 Chronic hepatitis B Full data in 1H 18

ONCOLYTIC VIRUSES

Pexa-Vec*

HCC – 1st line (PHOCUS)

HCC – 1st line

Other solid tumors

Sarcoma – Breast cancer

Solid tumors

First data 2019

First data in 2H 2018

TG6002 Glioblastoma First data in 2H 18

+ nivolumab (ICI) + CT

Neo-adjuvant (translational)

+ avelumab (ICI)

+ antiviral

+ sorafenib

+ ipilimumab (ICI)

+ nivolumab (ICI)

+ nivolumab (ICI)

+ cyclophosphamide

Neo-adjuvant (translational)

Ongoing FPI < 6 months

* Transgene has commercial rights to Pexa-Vec in Europe and additional selected countries. SillaJen has a co-promote option in five European countries.

Ideally suited for combination immunotherapy regimens

Therapeutic Vaccines

Our Therapeutic Vaccine platform

10

– Antigen (MUC1) expressionleading to maturation of Antigen Presenting Cell (APC)

– Mature APCs present MUC1antigen to naive T-cells

– Activated T-cells infiltrate the tumor, recognize and kill MUC1+ tumor cells

SC injection

Therapeutic vaccines express tumor/viral antigens

To stimulate a safe and specific immune response

– T-cells get activated , multiplyand reach the blood stream

Important benefit when combinedwith CT and ICIs

Modified Virus Ankara (MVA)

expressing MUC1 antigen & interleukin 2

TG4010 targeting 1st and 2nd line NSCLC

Clinical collaborations with

TG4010 | Strong lung cancer clinical data Improved response rate & duration of response

12

TG4010

+ CT

Placebo

+ CT

Non-squamous (n)

ORR

Median duration of response (wks)

98

40%

41

98

28%

18

✓ Improved response rate & duration of response

✓ Good safety profile

Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212)

TG4010 + chemotherapy (n=39)40.9 [23.9 – 54.1] wks

Chemotherapy (n=27)18.1 [13.7 – 36.4] wks

TG4010 + chemotherapy40.9 [23.9 – 54.1] wks

Placebo + chemotherapy18.1 [13.7 – 36.4] wks

TG4010 | Strong lung cancer clinical data Well positioned for further development in NSCLC

13

✓ Significant improvements in PFS and OS in patients in patients with non sq. tumors

✓ Clinical efficacy in both PD-L1 negative and PD-L1 positive patients

Progression-free survival (months)Patients with non sq. tumors (n=196)

Overall survival (months)Patients with non sq. tumors (n=196)

SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS)TG4010 in combination with chemotherapy for 1st line NSCLC

36%

20%

35%

19%

Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212)

TG4010 + chemotherapy

Placebo + chemotherapyTG4010 + chemotherapy

Placebo + chemotherapy

TG4010 | Proven mechanism of actionEfficacy driven by T-cell response (CD8+)

14Source: Tosch et al., Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC, Journal for ImmunoTherapy of Cancer, 2017 (5:70)

Specific CD8+ T cell response to MUC1 epitopes is associated with increased survival

OS improvement during TG4010 treatment is driven by the development of a larger CD8+ T cell anti-MUC1 repertory

Specific CD8+ T cell response to MUC1 after TG4010 administration is associated with responses against other lung tumor antigens

Increased CD8+ response without increase in inhibitory T reg frequency

- 100 000 200 000 300 000 400 000 500 000 600 000 700 000 800 000

2ND LINE (INDEPENDENT OF PD-L1 STATUS)

LOW PD-L1 - 1ST LINE

NON-MUTATED (ALK, EGFR, …)

NON-SQUAMOUS

STAGE IV

265 K

331 K

441 K

532 K

710 K

Eligible Population (US, EU, JP), in thousands of patients

TG4010 | Clinical positioningA very large population in NSCLC, stage IV, non-squamous patients

15

1L - TG4010 positioning

2L - TG4010 positioning

Source: Globocan, Company estimates

TG4010 | Clinical development plan (non sq. NSCLC)2 PoC trials to demonstrate the efficacy of TG4010 combined with ICIs

16

TG4010 + PD-1 Inhibitor

(nivolumab) NSCLC - 2nd line

• Multi-center Phase 2 trial in the US• PI: Dr. Karen Kelly (UC Davis)• BMS to supply nivolumab• First data expected 1Q 2018

Position TG4010 in all settings of advanced NSCLC in combination with PD-1 inhibitor

TG4010 + chemotherapy+ PD-1 Inhibitor

(nivolumab)

NSCLC - 1st linepatients with no or low level

of PD-L1 expression

• Multi-center Phase 1/2 trial in US and Europe• BMS to supply nivolumab• US FDA IND approval granted (Sept. 2017)• FPI expected to be enrolled end 2017• First data expected in 2H 2018

TG4010 | Non-Small Cell Lung Cancer (NSCLC) - 2nd linePhase 2 in combination with Opdivo® (nivolumab)

17

Endpoints

• Principal Investigator: Dr. Karen Kelly

• Collaborative arrangement

– UC Davis Medical Center, USA (sponsor)

– Bristol-Myers Squibb (supply of nivolumab)

– Transgene (supply of TG4010)

• First patient treated in March 2017

• First planned data expected 1Q 2018 (15 patients)

Support of

Primary endpoint: Objective response rate (ORR)•

Secondary endpoints: progression• -free survival (PFS), overall survival (OS), duration of response and safety

Protocol

• Up to 33 patients• Multi-center, single-arm, open-label study• Stage IV non-squamous NSCLC who have

progressed after one line of systemic therapy

Participating centers

• UC Davis• UC San Francisco

• City of Hope• UC San Diego

• Collaborative agreement with BMS (supply of nivolumab)

• US FDA IND Approval (Sept. 2017)

• First patient expected to be enrolled by the end of 2017

• First data expected in 2H 2018

TG4010 | Non-Small Cell Lung Cancer (NSCLC) - 1st linePhase 1/2 in combination with Opdivo® (nivolumab) + chemotherapy

18

Support of

Endpoints (Phase 2 part)

• Primary endpoint: Objective response rate (ORR)• Secondary endpoints: progression-free survival

(PFS), overall survival (OS), duration of response and safety

Protocol

• Up to 39 patients• Multi-center, single-arm, open-label study• Stage III B-IV or delayed relapse, tumors

with low or undetectable PD-L1 expression

• TG4010 108 PFU weekly for 6 weeks then every 3 weeks by SC route

• Nivolumab 360 mg every 3 weeks by IV route• Pemetrexed-carboplatin (or cisplatin) every 3 weeks for 4 cycles

Study regimen

Participating countries

USA•

Belgium•

• Denmark • France

MVA expressing HPV16 E6 & E7 antigens & interleukin 2

TG4001 targeting HPV-positivehead and neck cancer

Supported by

TG4001 | No specific treatment regimens for HPV+ head and neck cancer patients

20

~60% of oropharyngeal SCCHN are HPV+

• Increasing incidence in western countries 25,000 patients*

• Dismal prognosis

• Much better therapeutic options needed

Current treatment options for all head and neck cancer cases

First-line therapyFor patients with good • performance status: historically platinum-based doublet (e.g. Cisplatin/5-FU or carboplatin/paclitaxel)

ORR: – 30% to 40%

Median OS: – 6-9 months regardless of specific drug

For patient with poor • performance status: use single agent CT or cetuximab

Second-line therapyNivolumab, pembrolizumab•

ORR: – 16% to 19%

Median OS: – 7-8 months

Significant opportunity for TG4001 to improve the ORR of ICIs in a large head and neck cancer population

* Source: Globocan, Company estimates

• TG4001 - already demonstrated efficacy in the clinic: – Randomized, placebo-controlled Phase 2b (n=206) in HPV+ high grade cervical carcinoma in

situ (CIN2/3) – Demonstrated immunogenicity– Demonstrated efficacy (resolution and viral clearance) – Study confirmed safety (injection site reaction – most common adverse event) – TG4001 was nevertheless not progressed further in CIN 2/3 (LEEP efficacy)

• Thanks to KOLs and Merck KGaA/Pfizer’s commitment, decision to progress rather in advanced HPV positive cancers in combination with avelumab

TG4001 | Strong rationale for combining a vaccine targeting HPV with an ICI in advanced/metastatic HPV-positive SCCHN

21

Very strong scientific rationale for combining TG4001 and avelumab to address the high unmet medical in this important HPV-positive cancer population

TG4001 | HPV + Head & Neck Cancers (SCCHN)On-going Phase 1b/2 in combination with avelumab (Bavencio®)

22

• Lead investigator: Prof Christophe Le Tourneau, Institut Curie

• Collaborative agreement with the alliance of Merck KGaA and Pfizer (supply of avelumab)

• First patient treated in September 2017

Support of

Endpoints (Phase 2 part)• Primary endpoint: Objective response rate (ORR)• Secondary endpoints: progression-free survival (PFS),

overall survival (OS), duration of response and safety

First data expected in 2H 2018

Protocol

• Up to 50 patients (France)• Multi-center, single-arm, open-label trial• Metastatic or refractory/recurrent HPV-16+ head &

neck cancers, after failure of standard therapy

Modified Adenovirus 5 that expresses 3 different HBV (Hepatitis B Virus) antigens

TG1050 targeting chronic hepatitis B

TG1050 | Current therapies focus on disease management, not cure

24

Large unmet medical need as cure rate is extremely low

Need to improve clinical outcome:High risk of developing cirrhosis and hepatocellular carcinoma

500,000 eligible patients*

Treatment recommendations (EASL 2017 clinical guidelines)

Long• -term administration of entecavir (Baraclude®), tenofovir disoproxil fumarate (Viread®) or tenofovir alafenamide (Vemlidy®) as monotherapy

High level of viral suppression – 9̴8 %

Low level of functional cure (HBsAg loss) < – 3 % per year

PegIFN• for 48 weeks in highly selected patientsModerate level of viral suppression – 5̴0 %Low level of functional cure < – 9% per year

* Source: Decision Resources, Company estimates | Note: Includes patients from the US, EU, and Japan

• Only viral-based therapeutic vaccine that integrates the 3 relevant HBV antigens (polymerase, core, HBsAg)

• Demonstrated immunogenicity & functionality

– Similar to those of spontaneous resolvers i.e. robust and broad CD8 T-cell responses

– Capacity of HBV-specific T cells induced by TG1050 to recognize epitopes all HBV genotypes

– Capacity to induce functional T-cells in tolerant HBV mouse models (Novel AAV-based model, other)

• Antiviral properties

– Capacity to control HBsAg and induce HBsAg seroconversion with no detectable liver inflammation in tolerant HBV mouse models

• Ongoing preclinical experiments (direct/indirect antivirals, immuno-modulators,…)

TG1050 | Strong pre-clinical data Sustained anti-viral effects in HBV mouse models (AAV)

25

HBV DNA (viral load)Mean viral load at D28 : 1.4x106 copies/mL

HB

V D

NA

Fo

ld C

han

ge(M

ean

+/-

SEM

)

0.01

0.1

1

10

28 39 55 67 84 105 126 147 158

Days post AAV-HBV injection

Circulating HBsAgMean HBsAg titers at D28 : 20µg/mL

HB

sAg

Fold

Ch

ange

(Me

an +

/-SE

M)

0.1

1

28 39 55 67 84 105 126 147 158

2

0.5

Days post AAV-HBV injectionMartin et al., Gut, 2014Inschauspé et al., EASL, 2015

TG1050

Empty Ad

TG1050

Empty Ad

TG1050 | Phase 1/1b trial

26

Primary objectives✓ Evaluate safety and tolerability of TG1050

administered in single and multiple doses (3 injections at one week interval)

✓ Determine dose and schedule of administration for further development

Secondary endpoints✓ Antiviral activity: HBsAg levels✓ Cellular and humoral immune responses

Phase I/Ib enrolment completed

Preliminary data (AASLD Liver Meeting 2017):✓ Good safety profile in 12 patients✓ TG1050 induces a robust specific cell-mediated

immune response in patients that have received a single dose of TG1050

Principal investigator• Prof Fabien Zoulim,

Hospices civils, Lyon (France)

Protocol• Up to 48 patients• International, randomized safety and dose-

finding study• Patients currently being treated with

standard-of-care antiviral therapy (tenofovir or entecavir)

• Initial safety data in 12 patients reported• First efficacy data expected 1H 2018

(n=48)

Participating countries• Canada, France, Germany

A new highly promising therapeutic class in the fight against cancer

Oncolytic Viruses – Pioneered by Transgene

Our Oncolytic Virus (OV) platformIT/IV administration to directly attack tumor cells and stimulate immune response

28

Preclinical models show OV’s ability to reduce tumor burden and have an abscopal effect on distant metastasis via induced immunogenic

cell death mechanism

OV infect tumor cells where they selectively replicate

Active payloads are expressed locally and released into the tumor micro-environment

Cytotoxic T-cells enter into the tumor, attracted by local inflammation and danger signalsInfiltrated T-cells kill tumor cells and boost anti-tumor response by active release of tumor antigens

This replication leads to immunogenic cell death, virus propagation in neighboring cells and “in situ” vaccination

Replicative Vaccinia Virus expressing GM-CSF

Pexa-Vec in hepatocellular carcinoma (HCC)

Pexa-Vec | Collaboration with SillaJen

Ongoing pivotal Phase 3 trial in HCC 1LSillaJen responsible for conducting •

Phase 3 trial

Transgene own all rights for its territory•

Transgene’s remaining funding obligation •

amounts to $1.5 million

30

Transgene owns development and commercialization rights in Europe

EU rights of Pexa-Vec in-licensed in 2010 Current licensor: SillaJen (KOSDAQ: 215600)

4 Phase 2 trials conducted by Transgene

Pexa-Vec | Large unmet medical need in HCC

31

Dismal prognosis

Better therapeutic options needed

25,000 eligible patients in Europe*

First-line therapy

Sorafenib is currently the only approved product • - modest activity

ORR: – 2% ; median OS: 10.7 months

Nivolumab could become a new therapeutic option: Promising activity •

in Phase 2 (still ongoing)

Second-line therapy

Regorafenib •

ORR: – 10%; median OS: 10.6 months

Nivolumab recently approved by FDA•

ORR: – 18%; median OS: 15.6 months

* Source: Globocan, Company estimates

Pexa-Vec | Key Phase 2 clinical trial resultsClinical activity demonstrated in multiple trials

32

Proof of concept for MOA: active immunotherapy

30-patient dose-finding Phase 2 trial in HCC (80% of patients first-line)• OS results - high dose versus low dose

– Median OS: 14.1 (high dose) vs. 6.7 months (low dose)

– Hazard Ratio = 0.39

– p = 0.020

Nature Medicine, Volume 19, Issue 2, February 2013

Trials with >300 patients treated with Pexa-Vec in variety of tumor types, including liver, colorectal and kidney

Pexa-Vec | Clinical development plan in HCC - 1st linePivotal Phase 3 and combination Phase 2

33

Pexa-Vec + Opdivo® (nivolumab)

Advanced HCC1st line

• Multi-center Phase 1/2 trial in France, Italy, US• Sponsor: Transgene• Open-label, single-arm trial• 1st patient dosed in July 2017• Efficacy data expected in 2H 2018

Pexa-Vec + sorafenib

Advanced HCC1st line

• Multi-center Phase 3 trial in Europe, US, Asia• Randomized, two arm trial• Ongoing recruitment • First data (efficacy vs SoC) expected in 2019

Position Pexa-Vec with SoC treatment for all PD-L1 status patients

Pexa-Vec | Ongoing Phase 3 clinical trial (PHOCUS trial)1st line advanced hepatocellular carcinoma

34

Conducted by

Phase 3 study in combination with sorafenib (Kinase inhibitor)

✓ Orphan drug designation granted✓ SPA with FDA✓ SFDA authorization (July 2017)

Pexa• -Vec + sorafenib versus sorafenib (only approved drug for advanced HCC)

N=• 600 patients (Europe, North America, and Asia), 140 clinical centers

1:1 • randomized trialDesign

Endpoints

Primary: overall survival (OS)•

Secondary: safety, time to progression, progression• -free survival, overall response rate and disease control rate

• First patient enrolled in January 2016• Recruitment ongoing • First efficacy data expected in 2019

Pexa-Vec | Phase 1/2, combo with nivolumab Advanced stage HCC - 1st line

35

Principal Investigator: Prof Olivier Rosmorduc, Pitié-Salpêtrière Hospital, Paris (France)

First patient treated in July 2017

Protocol• Up to 36 patients• Multi-center, open label trial• Patients with advanced-stage HCC,

treatment naive

Endpoints (Phase 2 part)• Primary endpoint: Objective response rate (ORR)• Secondary endpoints: progression-free survival (PFS), overall

survival (OS), duration of response and safety• Exploratory endpoints: extended translational program

(PDL1 …) including biopsy during treatment

Pexa• -Vec: 3 intratumoral injections, 109 pfu, q2w +/- boostsNivolumab: IV, • 240mg, q2w until progression, start at D15

Study regimen

Participating countries• France, Italy, US

Efficacy data expected in 2H 2018

Oncolytic viruses | Our clear roadmap for success

36

Time to market

Level of innovation

Imlygic/T-Vec, Pexa-Vec

NEW GENERATIONTG6002

FUTURE GENERATIONS

• Oncolytic activity

• IT administration

• Indirect immune stimulation, via non-specific immune modulators (e.g. GM-CSF)

Oncolytic activity•

Systemic (IV) administration•

Better tumor selectivity •

(double gene deletion)

Additional functionality • -targeted chemotherapy

• Oncolytic activity

• Systemic (IV) administration

• Better tumor selectivity (double gene deletion)

• “Armed” – targeted immune modulators expressed in tumor microenvironment

TG6002 | First product incorporating our newest vectorImproved virus and advanced therapeutic payload

37

FCU1 gene

Prodrug5-FC

Cytotoxic drug5-FU

Prodrug activating enzyme

Cell

deathTargeted chemotherapy

• Proprietary virus• Double gene deletion TK- RR-

Viral oncolysis

• Phase 1 trial in glioblastoma, open label, dose escalation, IV administration• PI: Prof A. Idbaih, MD, PhD (Pitié Salpêtrière Hospital, France) • INCA Grant • First data in 2H 18

First-in-human trial1st patient treated in Oct. 2017

Development in GI cancersin active preparation

Superior oncolytic properties with local production of chemotherapy

Significant anticipated value-creating news flow through 2018Clinical readouts expected on all 5 products

38

5 productsin the clinic

TG4010 Lung cancer (NSCLC)

TG4001 HPV+ head & neck cancer (SCCHN)

TG1050 Chronic hepatitis B (HBV)

Pexa-Vec Liver cancer (HCC)

TG6002 Glioblastoma

First Phase 2 data 1Q 2018 (2nd line, TG4010 + nivolumab)

First Phase 2 data in 2H 2018 (TG4001 + avelumab)

Full Phase 1b data in 1H 2018

Phase 2 efficacy data in 2H 2018 (Pexa-Vec + nivolumab)

First Phase 1 data 2H 2018

Appendices

39

Company funded to deliver multiple value generating milestones

40

Free float40 %

60 %

Key shareholdersAs of September 30, 2017

• Market capitalization:~ €200 million as of September 30, 2017

• 56.4 million shares outstanding+ 1.1 million options and restricted stocks

• Listed on Euronext Paris• ISIN: FR0005175080 - Ticker: TNG

Key figures

Expected cash burn 2017

(~€ 14 million for 4Q 2017)~ € 30 million

Operating revenuesas of September 30, 2017

~ € 5 million

Cash and cash equivalentsas of September 30, 2017

€ 40 million

€10 million drawn down

(Due 2021)

Our strategy |Develop future disruptive innovationEngineer multifunctional oncolytic viruses

41

Anti-cancer Weapons

Patented Viruses

VV

TK- RR-

Cytokines / Chemokines

Receptor ligandsAntibodySdAb

Enzyme

+

Oncolytic activityImmunogenic properties

Tumor targeting from the IV route

Key effectors of the tumor microenvironmentPotent immunomodulators benefiting from local delivery

Our strategy |Develop future disruptive innovationEngineer viruses that attack the tumor at multiple points

42

Cellular

Organism

Tumor microenvironment

Improved• replication in resistant tumor cellsImproved • lytic activity + release of immunogenic components

• Mobilization of innate + adaptive responses• Systemic efficacy

• Attraction + infiltration of effector immune cells • Breakdown of immunosuppressive mechanisms

ICI clinical collaboration scheme

43

General approach

• Proof-of-concept trials• Collaborative design of the protocol with shared

expectations for outcomes• Open-label trials with joint access to results• No preferential rights granted over TG4010 or

TG4001

• Partner to provide ICI for the trial and participate in clinical sites selection

• Transgene to provide its product, fund the trials and ensure their execution

• TG4010, 1L, advanced lung cancer

• TG4010, 2L, advanced lung cancer

• TG4001, 2L, HPV+ head and neck cancers

3 ongoing clinical collaborations

TG4001 | Positive Phase 2b in HPV-associated CIN 2/3Demonstration of statistically significant curative activity at 6 months

44

0

5

10

15

20

25

30

35

40

HPV16 All Genotypes

P = 0.009 p = 0.0013

Resolution (%) Viral clearance (%) ✓ Single agent TG4001 is active, and able to address HPV-related carcinomas

✓ Data represent a strong POC of active immunotherapy‒ TG4001 was 5x superior in HPV16 patients

compared to placebo to induce complete disease regression

‒ TG4001 showed an efficacy 4 fold superior compared to placebo regarding the viral clearance

✓ Clinical experience in 300+ subjects, demonstrating good safety profile ‒ Injection site reactions were the most

common AE

PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 206 PATIENTS)in patients with cervical carcinoma in situ of high grade (2/3)

0

5

10

15

20

25

HPV16 All Genotypes

TG4001monotherapy

Placebo

P = 0.0498 P = 0.0126

400 Boulevard Gonthier d’Andernach - Parc d’Innovation - CS80166 67405 Illkirch Graffenstaden Cedex France

Tél.: + 33 (0)3 88 27 91 21 www.transgene.fr

Lucie LarguierDirector Corporate Communication and Investor Relations+33 3 88 27 91 04 / +33 6 76 24 72 27

larguier@transgene.fr / investorrelations@transgene.fr

Contact

@TransgeneSA Transgene